Heron Therapeutics, Inc. (HRTX) Holdings Increased by Virtu KCG Holdings LLC

Virtu KCG Holdings LLC raised its position in Heron Therapeutics, Inc. (NASDAQ:HRTX) by 62.5% in the second quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The fund owned 25,053 shares of the biotechnology company’s stock after acquiring an additional 9,637 shares during the quarter. Virtu KCG Holdings LLC’s holdings in Heron Therapeutics were worth $347,000 at the end of the most recent reporting period.

Other hedge funds have also recently made changes to their positions in the company. Legal & General Group Plc lifted its stake in Heron Therapeutics by 13.9% in the first quarter. Legal & General Group Plc now owns 8,971 shares of the biotechnology company’s stock valued at $136,000 after acquiring an additional 1,098 shares during the last quarter. Quantbot Technologies LP lifted its stake in Heron Therapeutics by 2,619.6% in the second quarter. Quantbot Technologies LP now owns 12,483 shares of the biotechnology company’s stock valued at $172,000 after acquiring an additional 12,024 shares during the last quarter. Tudor Investment Corp ET AL acquired a new stake in Heron Therapeutics in the first quarter valued at $253,000. Nationwide Fund Advisors lifted its stake in Heron Therapeutics by 11.3% in the first quarter. Nationwide Fund Advisors now owns 21,972 shares of the biotechnology company’s stock valued at $330,000 after acquiring an additional 2,233 shares during the last quarter. Finally, American International Group Inc. lifted its stake in Heron Therapeutics by 38.6% in the first quarter. American International Group Inc. now owns 25,332 shares of the biotechnology company’s stock valued at $380,000 after acquiring an additional 7,059 shares during the last quarter.

Heron Therapeutics, Inc. (NASDAQ HRTX) opened at 15.35 on Tuesday. The stock has a 50 day moving average of $15.97 and a 200 day moving average of $15.18. Heron Therapeutics, Inc. has a 12 month low of $12.21 and a 12 month high of $20.85. The company’s market capitalization is $831.02 million.

Heron Therapeutics (NASDAQ:HRTX) last issued its quarterly earnings results on Wednesday, August 9th. The biotechnology company reported ($0.80) earnings per share for the quarter, topping the Zacks’ consensus estimate of ($0.90) by $0.10. The company had revenue of $8.51 million during the quarter, compared to analysts’ expectations of $4.53 million. Equities analysts anticipate that Heron Therapeutics, Inc. will post ($3.51) EPS for the current fiscal year.

COPYRIGHT VIOLATION NOTICE: This news story was first published by The Ledger Gazette and is the sole property of of The Ledger Gazette. If you are viewing this news story on another publication, it was copied illegally and reposted in violation of U.S. & international copyright legislation. The original version of this news story can be viewed at https://ledgergazette.com/2017/10/17/heron-therapeutics-inc-hrtx-holdings-increased-by-virtu-kcg-holdings-llc.html.

A number of analysts have commented on HRTX shares. Cantor Fitzgerald set a $31.00 price target on shares of Heron Therapeutics and gave the company a “buy” rating in a research note on Friday, August 18th. Jefferies Group LLC reiterated a “buy” rating on shares of Heron Therapeutics in a research note on Wednesday, August 16th. Noble Financial reiterated a “buy” rating on shares of Heron Therapeutics in a research note on Thursday, August 10th. Cowen and Company set a $40.00 price target on shares of Heron Therapeutics and gave the company a “buy” rating in a research note on Thursday, August 3rd. Finally, Aegis reiterated a “buy” rating and issued a $33.00 price target on shares of Heron Therapeutics in a research note on Tuesday, July 18th. One analyst has rated the stock with a sell rating, one has assigned a hold rating and eleven have assigned a buy rating

Other hedge funds have also recently made changes to their positions in the company. Legal & General Group Plc lifted its stake in Heron Therapeutics by 13.9% in the first quarter. Legal & General Group Plc now owns 8,971 shares of the biotechnology company’s stock valued at $136,000 after acquiring an additional 1,098 shares during the last quarter. Quantbot Technologies LP lifted its stake in Heron Therapeutics by 2,619.6% in the second quarter. Quantbot Technologies LP now owns 12,483 shares of the biotechnology company’s stock valued at $172,000 after acquiring an additional 12,024 shares during the last quarter. Tudor Investment Corp ET AL acquired a new stake in Heron Therapeutics in the first quarter valued at $253,000. Nationwide Fund Advisors lifted its stake in Heron Therapeutics by 11.3% in the first quarter. Nationwide Fund Advisors now owns 21,972 shares of the biotechnology company’s stock valued at $330,000 after acquiring an additional 2,233 shares during the last quarter. Finally, American International Group Inc. lifted its stake in Heron Therapeutics by 38.6% in the first quarter. American International Group Inc. now owns 25,332 shares of the biotechnology company’s stock valued at $380,000 after acquiring an additional 7,059 shares during the last quarter.

Heron Therapeutics, Inc. (NASDAQ HRTX) opened at 15.35 on Tuesday. The stock has a 50 day moving average of $15.97 and a 200 day moving average of $15.18. Heron Therapeutics, Inc. has a 12 month low of $12.21 and a 12 month high of $20.85. The company’s market capitalization is $831.02 million.

Heron Therapeutics (NASDAQ:HRTX) last issued its quarterly earnings results on Wednesday, August 9th. The biotechnology company reported ($0.80) earnings per share for the quarter, topping the Zacks’ consensus estimate of ($0.90) by $0.10. The company had revenue of $8.51 million during the quarter, compared to analysts’ expectations of $4.53 million. Equities analysts anticipate that Heron Therapeutics, Inc. will post ($3.51) EPS for the current fiscal year.

COPYRIGHT VIOLATION NOTICE: This news story was first published by The Ledger Gazette and is the sole property of of The Ledger Gazette. If you are viewing this news story on another publication, it was copied illegally and reposted in violation of U.S. & international copyright legislation. The original version of this news story can be viewed at https://ledgergazette.com/2017/10/17/heron-therapeutics-inc-hrtx-holdings-increased-by-virtu-kcg-holdings-llc.html.

A number of analysts have commented on HRTX shares. Cantor Fitzgerald set a $31.00 price target on shares of Heron Therapeutics and gave the company a “buy” rating in a research note on Friday, August 18th. Jefferies Group LLC reiterated a “buy” rating on shares of Heron Therapeutics in a research note on Wednesday, August 16th. Noble Financial reiterated a “buy” rating on shares of Heron Therapeutics in a research note on Thursday, August 10th. Cowen and Company set a $40.00 price target on shares of Heron Therapeutics and gave the company a “buy” rating in a research note on Thursday, August 3rd. Finally, Aegis reiterated a “buy” rating and issued a $33.00 price target on shares of Heron Therapeutics in a research note on Tuesday, July 18th. One analyst has rated the stock with a sell rating, one has assigned a hold rating and eleven have assigned a buy rating to the stock. Heron Therapeutics presently has an average rating of “Buy” and an average price target of $28.50.

Heron Therapeutics Company Profile

Heron Therapeutics, Inc is a biotechnology company engaged in developing pharmaceutical products for patients suffering from cancer or pain. The Company’s product candidates include SUSTOL, HTX-019 and HTX-011. All of its product candidates utilize science and technology platforms, including its Biochronomer drug delivery technology.

Want to see what other hedge funds are holding HRTX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Heron Therapeutics, Inc. (NASDAQ:HRTX).

Institutional Ownership by Quarter for Heron Therapeutics (NASDAQ:HRTX)

Receive News & Ratings for Heron Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Heron Therapeutics Inc. and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply